doi: 10.2337/diaclin.34.2.81.
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
Affiliations
- PMID: 27092017
- PMCID: PMC4833487
- DOI: 10.2337/diaclin.34.2.81
Item in Clipboard
Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
Clin Diabetes.
2016 Apr.
Abstract
In Brief In the past decade, various incretin-based therapies have emerged in clinical practice. These drugs, including dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists lower A1C with weight-neutral or weight-lowering effects and a relatively lower risk of hypoglycemia. This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes.
Similar articles
-
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Int J Clin Pharm. 2013. PMID: 23263796 Review.
-
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.World J Diabetes. 2014 Feb 15;5(1):40-51. doi: 10.4239/wjd.v5.i1.40. World J Diabetes. 2014. PMID: 24567800 Free PMC article. Review.
-
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.Adv Ther. 2013 Feb;30(2):81-101. doi: 10.1007/s12325-013-0009-4. Epub 2013 Feb 13. Adv Ther. 2013. PMID: 23423907 Review.
-
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591. Epub 2016 Jan 5. Diabetes Obes Metab. 2016. PMID: 26489970 Free PMC article. Review.
-
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Diabetes Obes Metab. 2012. PMID: 22471248 Review.
Cited by
-
Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.Diabetes Ther. 2023 Apr;14(4):653-669. doi: 10.1007/s13300-023-01369-6. Epub 2023 Feb 21. Diabetes Ther. 2023. PMID: 36809495 Free PMC article.
-
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.Pediatr Diabetes. 2022 Sep;23(6):641-648. doi: 10.1111/pedi.13343. Epub 2022 Apr 24. Pediatr Diabetes. 2022. PMID: 35411611 Free PMC article. Clinical Trial.
-
Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.PLoS One. 2018 May 22;13(5):e0196312. doi: 10.1371/journal.pone.0196312. eCollection 2018. PLoS One. 2018. PMID: 29787591 Free PMC article.
-
Lixisenatide: A New Option for Managing Type 2 Diabetes.J Pharm Technol. 2017 Oct;33(5):195-203. doi: 10.1177/8755122517711958. Epub 2017 Jun 7. J Pharm Technol. 2017. PMID: 34860974 Free PMC article.
References
-
- Zunz E, LaBarre J. Contributions a l’etude des variations physiologiques entre des la secretion intune du pancreas: relations entre les secretions externe et interne du pancreas. Arch Int Physiol Biochem 1929;31:20–44 [in French]
-
- LaBarre J, Still EU. Studies on the physiology of secretin. Am J Physiol 1930;91:649–653
-
- Loew ER, Grey ES, Ivy AC. Is a duodenal hormone involved in carbohydrate metabolism? Am J Physiol 1940;129:659–663
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
